Theravance Biopharma, Inc. - Ordinary Shares (TBPH): Price and Financial Metrics
TBPH Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for TBPH is -0.32 -- better than only 6.3% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -2.47 for Theravance Biopharma Inc; that's greater than it is for only 4.58% of US stocks.
- Theravance Biopharma Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -24.03%, greater than the shareholder yield of just 10.15% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Theravance Biopharma Inc, a group of peers worth examining would be ASMB, CYCN, BLUE, ACIA, and FGEN.
- TBPH's SEC filings can be seen here. And to visit Theravance Biopharma Inc's official web site, go to www.theravance.com.
TBPH Stock Price Chart Interactive Chart >
TBPH Price/Volume Stats
| Current price | $16.89 | 52-week high | $31.35 |
| Prev. close | $17.31 | 52-week low | $14.48 |
| Day low | $16.67 | Volume | 56,690 |
| Day high | $17.61 | Avg. volume | 350,142 |
| 50-day MA | $18.48 | Dividend yield | N/A |
| 200-day MA | $19.45 | Market Cap | 1.08B |
Theravance Biopharma, Inc. - Ordinary Shares (TBPH) Company Bio
Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company was founded in 2013 and is based in George Town, the Cayman Islands.
Latest TBPH News From Around the Web
Below are the latest news stories about Theravance Biopharma Inc that investors may wish to consider to help them evaluate TBPH as an investment opportunity.
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2020 Results - Earnings Call TranscriptTheravance Biopharma, Inc. (TBPH) Q4 2020 Earnings Conference Call February 23, 2021, 05:00 PM ET Company Participants Gail Cohen - VP, Corporate Communications and IR Rick Winningham - CEO Frank Pasqualone - Chief Commercial Operations Officer Brett Haumann - Chief Medical Officer Andrew Hindman - CFO Conference Call Participants Geoffrey... |
Theravance Biopharma Earnings PreviewTheravance Biopharma (NASDAQ:TBPH) releases its next round of earnings this Tuesday, February 23. Here is Benzinga's essential guide to Theravance Biopharma's Q4 earnings report. Net Income, Earnings, And Earnings Per Share Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Sell-side analysts are expecting Theravance Biopharma's loss per share to be near $1.02 on sales of $20.85 million. In the same quarter last year, Theravance Biopharma announced EPS of $1.17 on revenue of $29.50 million. Why Analyst Estimates And Earnings Surprises Are Important Ana... |
Theravance Biopharma to Participate in Upcoming Investor ConferencesTheravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows: |
2 “Strong Buy” Stocks Trading at Steep Discountsreward combination will work toward long-term advantage. So, how are investors supposed to distinguish between the names poised to get back on their feet and those set to remain down in the dumps? That’s what the pros on Wall Street are here for. Using TipRanks’ database, we pinpointed two beaten-down stocks the analysts believe are gearing up for a rebound. |
Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare ConferenceTheravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, will webcast its presentation at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 2:00 p.m. ET (11:00 a.m. PT/7:00 p.m. GMT). A webcast of the presentation may be accessed by visiting the "Investors" section of the Company's website at https://investor.theravance.com/events-and-presentations, and the replay will be archived for 30 days. |
TBPH Price Returns
| 1-mo | -11.52% |
| 3-mo | 2.93% |
| 6-mo | -2.48% |
| 1-year | -29.39% |
| 3-year | -39.79% |
| 5-year | 4.65% |
| YTD | -4.95% |
| 2020 | -31.36% |
| 2019 | 1.17% |
| 2018 | -8.25% |
| 2017 | -12.52% |
| 2016 | 94.51% |
Continue Researching TBPH
Here are a few links from around the web to help you further your research on Theravance Biopharma Inc's stock as an investment opportunity:Theravance Biopharma Inc (TBPH) Stock Price | Nasdaq
Theravance Biopharma Inc (TBPH) Stock Quote, History and News - Yahoo Finance
Theravance Biopharma Inc (TBPH) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...